Innovative Nanoparticles Release Vaccine Through Perspiration
Main Category: Immune System / VaccinesAlso Included In: Infectious Diseases / Bacteria / Viruses
Article Date: 19 May 2010 - 5:00 PDT
'Innovative Nanoparticles Release Vaccine Through Perspiration'
| Patient / Public: | ![]() |
3 (1 votes) |
| Healthcare Prof: | ![]() |
4 (1 votes) |
The Helmholtz Centre for Infection Research (HZI) has received a grant through the current round of the funding programme "Grand Challenges Explorations" of the Bill & Melinda Gates Foundation. The programme is supporting a global health project for development of nanoparticles that release the vaccine active ingredients through the skin upon contact with perspiration. The Braunschweig Helmholtz Centre for Infection Research (HZI) is implementing the research project POLMITRANSVAC (Pollen Mimetic Transcutaneous Vaccination) in cooperation with the Helmholtz Institute for Pharmaceutical Research Saarbrucken (HIPS). Successful projects have the opportunity to receive a follow-on grant of up to $1 million US in a second phase.
"We are linking for the first time our expertise at the HZI in the development of vaccines with multi-year experience regarding the formulation of active ingredients in nanoparticles, which the scientists at HIPS in Saarbrücken have available", say the scientists Carlos Alberto Guzmán from the HZI, Claus-Michael Lehr and Steffi Hansen from HIPS, as well as Ulrich Schäfer from the Saarland University.
"The novel concept in our method is the pathway through which the vaccine is administered. The nanoparticles penetrate via the hair follicles into the skin, then come into contact with human perspiration and release the active vaccine ingredients, mimicking what normally occurs during pollen sensitization. This method of vaccination by-passes the traditional and more painful needle-based vaccines and has the potential to stimulate mucosal immune responses.
The research project of the Helmholtz Centre for Infection Research is one of 78 research projects which are being funded by the Gates Foundation in the fourth round of "Grand Challenges Explorations". The initiative is intended to support worldwide researchers and strategies for diagnosis and avoidance of infectious diseases, and to develop improvements in family health. The selection process took into consideration 2,700 applications that had been submitted. Overall, the Foundation research projects support 19 countries on six continents.
"Grand Challenges Explorations continues to generate unique and creative ideas aimed at tackling global health issues" explained Tachi Yamada, president of the World Health Programme of the Gates Foundation. "We are convinced that a few of these ideas can and will lead to new innovations and ultimately to new solutions that will save lives."
Source:
Susanne Thiele
Helmholtz Association of German Research Centres
Visit our immune system / vaccines section for the latest news on this subject.
MLA
25 May. 2012. <http://www.medicalnewstoday.com/releases/189228.php>
APA
http://www.medicalnewstoday.com/releases/189228.php.
Please note: If no author information is provided, the source is cited instead.
Add Your Opinion On This Article
'Innovative Nanoparticles Release Vaccine Through Perspiration'Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




